Editorial Board

2024-9-1

Food for thought- Paving the way for a UK Roadmap towards optimum consumer safety: Development, Endorsement and Regulatory Acceptance of New Approach Methodologies (NAMs) in Chemical Risk Assessment and Beyond

2024-9-1

Aspects of complexity in quality and safety assessment of peptide therapeutics and peptide-related impurities. A regulatory perspective.

2024-9-1

PBPK Modeling Demonstrates that Exposure Time Adjustment is Unnecessary for Setting an Acute Manganese Inhalation Exposure Guideline

2024-9-1

Neurobehavioral assessment of BMEDA by modified Irwin test in Sprague-Dawley rats

2024-9-1

Toxicity Reference Values for Force Health Protection: Provisional Occupational Exposure Guidelines

2024-9-1

Safety Assessment of Protein A and Derivation of a Parenteral Health-Based Exposure Limit

2024-9-1

Biomonitoring of 2,4-dichlorophenoxyacetic acid (2,4-D) herbicide: A global view

2024-8-19

Toxicity Reference Values (TRVs) for Force Health Protection: Gap Identification and TRV Prediction

2024-8-13

Lanthanum nitrate demonstrated no genotoxicity in the conducted tests

2024-8-1

Editorial Board

2024-8-1

Historical control data of rare events: issues, chronological patterns and their relevance for toxicological evaluations

2024-8-1

Urinary MicroRNA biomarkers of nephrotoxicity in Macaca fascicularis

2024-8-1

WORKING TITLE: Prenatal Developmental Toxicity Studies of Allyl Alcohol in Rats and Rabbits

2024-8-1

Letter to the Editors regarding “Inter-laboratory validation of bioaccessibility testing for metals” by

2024-8-1

Review of dose setting for the extended one-generation reproductive toxicity studies (OECD TG 443): Considerations on ECHA's dose level selection recommendations

2024-8-1

The need for guidance in antidepressant drug development: Revisiting the role of the forced swim test and tail suspension test

2024-8-1

Two-year carcinogenicity study of a novel plasticizer, bis(2-ethylhexyl) cyclohexane-1,4-dicarboxylate (Eco-DEHCH), by oral diet in Han Wistar rats

2024-8-1

The database makes the poison: How the selection of datasets in QSAR models impacts toxicant prediction of higher tier endpoints

2024-8-1

Retrospective Application of ICH M7 to Anti-Hypertensive Drugs in Brazil: Risk Assessment of Potentially Mutagenic Impurities

2024-8-1

A sustainable and innovative method to determine parabens in body creams for exposure and risk assessment

2024-8-1

Resource and animal use implications of the proposed REACH information requirements for endocrine disruptor assessment

2024-8-1

Endeavours made by trade associations, pharmaceutical companies and regulators in the replacement, reduction and refinement of animal experimentation in safety testing of pharmaceuticals.

2024-8-1

Can next generation ecological risk assessment decisions be made today?―A case study of regulatory risk assessment in the United States

2024-7-4

N-Nitrosamine Impurity Risk Assessment in Pharmaceuticals: Utilizing In Vivo Mutation Relative Potency Comparison to Establish an Acceptable Intake for NTTP

2024-7-1

The use of weight-of-evidence approaches to characterize developmental toxicity risk for therapeutic monoclonal antibodies in humans without in vivo studies.

2024-7-1

Estimation of Acceptable Daily Intake Values based on Modeling and In Vivo Mutagenicity of NDSRIs of Fluoxetine, Duloxetine and Atomoxetine

2024-7-1

Grouping of short alkyl-chain branched carboxylic acids for developmental toxicity

2024-6-12

A UK Framework for the Assessment and Integration of Different Scientific Evidence Streams in Chemical Risk Assessment

2024-6-3

Metabolism-based category formation for the prioritisation of genotoxicity hazard assessment for plant protection product residues (Part 4): α-Chloroacetamides

2024-6-1

Comparison of Permitted Daily Exposure (PDE) Values for Active Pharmaceutical Ingredients (APIs) - Evidence of Robust Approach

2024-6-1

Biomonitoring equivalents for ethylene thiourea

2024-6-1

A roadmap towards a human-centric safety assessment of advanced therapy medicinal products

2024-6-1

In silico evaluation of the potential allergenicity of a fungal biomass from Rhizomucor pusillus for use as a novel food ingredient

2024-6-1

Prioritizing of potential environmental exposure carcinogens beyond IARC group 1 to 2B based on weight of evidence (WoE) approach

2024-6-1

Differences in the anatomy and physiology of the human and rat respiratory tracts and impact on toxicological assessments

2024-6-1

Editorial Board

2024-6-1

Proposals for new spray drift exposure values in orchard and vineyards for residents and bystanders

2024-6-1

Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA)

2024-6-1

A Weight of Evidence Evaluation of the Mode of Action of Isoeugenol

2024-6-1

Proposals for new transfer coefficient (TC) values for worker re-entry activities in grape vineyards

2024-6-1

Analysis of Non-Mutagenic Substances in the Context of Drug Impurity Assessment – Few are Potent Toxicants

2024-6-1

Regulatory Toxicology and Pharmacology New limits proposed for the management of non-mutagenic impurities

2024-6-1

Deriving acceptable limits for non-mutagenic impurities in medicinal products – Durational adjustments

2024-6-1

Testing of acute and sub-acute toxicity profile of novel naproxen sodium nanoformulation in male and female mice

2024-6-1

Hepatotoxicity of Silver Nanoparticles: Benchmark Concentration Modeling of an In Vitro Transcriptomics Study in Human iPSC-derived Hepatocytes

2024-5-31

Evaluation of the EMA Log Kow Trigger for Fish BCF Testing Based on Data for Several Human Pharmaceuticals

2024-5-31

Editorial Board

2024-5-1

Commentary: Value of information case study strongly supports use of the Threshold of Toxicological Concern (TTC)

2024-5-1

False positive findings associated with adenoviral vector-based vaccine underscore the regulatory necessity to eliminate abnormal toxicity test

2024-5-1